There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Precision Biosciences Inc is $48.74M. A total of 0.64 million shares were traded on the day, compared to an average of 1.50M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, DTIL has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 26 BUYs and 7 SELLs from insiders. Insiders purchased 1,050,221 shares during that period but sold 230,824.
In the most recent transaction, SMITH J. JEFFERSON sold 28,000 shares of DTIL for 0.37 per share on Jan 23. After the transaction, the Chief Research Officer now owns 1,987,269 company shares. In a previous transaction on Jan 22, Amoroso Michael sold 137,390 shares at 0.36 per share. DTIL shares that President and CEO owns now total 356,433.
Among the insiders who sold shares, List Alan disposed of 21,526 shares on Jan 22 at a per-share price of $0.36. This resulted in the Chief Medical Officer holding 94,982 shares of DTIL after the transaction. In another insider transaction, Scimeca Dario sold 21,287 shares at $0.36 per share on Jan 22. Company shares held by the General Counsel and Secretary now total 151,028.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for DTIL in the last 3 months, the mean price target is $2.63 with high estimates of $3.00 and low estimates of $2.00. In terms of 52-week highs and lows, DTIL has a high of $1.29 and a low of $0.28.
As of this writing, DTIL has an earnings estimate of -$0.07 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $0.1 per share and a lower estimate of -$0.17. The company reported an EPS of -$0.1 in the last quarter, which was 58.30% higher than expectations of -$0.24.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. DTIL’s latest balance sheet shows that the firm has $143.66M in Cash & Short Term Investments as of fiscal 2021. There were $9.11M in debt and $35.98M in liabilities at the time. Its Book Value Per Share was $0.25, while its Total Shareholder’s Equity was $91.17M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DTIL is Buy with a score of 4.20.